Redeye initiates coverage of Active Biotech with a cautiously optimistic view on the new strategic direction. Increased clinical activity sets the shares up for several catalysts during the next year. The Company is currently raising SEK 76m in a Rights Issue. If the capital raise is fully subscribed, we calculate a base case of SEK 3 per share.